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ABSTRACT  
The TNF family ligand ectodysplasin A (EDA) is produced as two full-length splice 
variants, EDA1 and EDA2, that bind to EDA receptor (EDAR) and X-linked EDA receptor 
(XEDAR/EDA2R) respectively. Inactivating mutations in the genes EDA or EDAR genes cause 
hypohidrotic ectodermal dysplasia (HED) with malformation of teeth, hair and glands, while 
milder deficiencies affect teeth only. EDA acts early during development of ectodermal 
appendages as early as the embryonic placode stage, and also plays a role in adult appendage 
function. We detected three- to fourfold higher levels of circulating EDA in cord blood than in 
adult sera. A receptor binding-competent form of EDA1 was the main form of EDA, but a minor 
fraction of EDA2 was also found in fetal bovine serum. Sera of EDA-deficient patients contained 
either background EDA levels or low levels of EDA that could not bind to recombinant EDAR. 
Serum of a patient with a V262F missense mutation in EDA causing a milder form of X-linked 
HED (XLHED) contained low levels of EDA capable of binding to EDAR. In two mildly 
affected carriers, intermediate levels of EDA were detected, while a severely affected carrier had 
no active EDA in serum. Small amounts of EDA were also detectable in normal adult saliva. 
Finally, EDA could be measured in spots of wild-type adult or cord blood dried onto filter paper 
at levels significantly higher than in EDA-deficient blood. Measurement of EDA levels 
combined with a receptor-binding assay might be of relevance to aid diagnosis of total or partial 
EDA deficiencies. 
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INTRODUCTION 
EDA is a TNF family member important for the development of ectodermal appendages in 
vertebrates (Harris et al. 2008; Kere et al. 1996; Monreal et al. 1998; Srivastava et al. 1997). 
EDA-deficiency in humans causes X-linked hypohidrotic ectodermal dysplasia (XLHED), a 
congenital disorder characterized by hypoplastic hair, teeth and sweat glands (Visinoni et al. 
2009). The EDA protein consists of a short intracellular domain, a membrane spanning segment, 
a stalk region, a consensus furin cleavage site, a short proteoglycan-interacting sequence, an 
oligomerizing collagen domain and a C-terminal TNF homology domain that forms homotrimers 
and binds to receptors (Chen et al. 2001; Schneider et al. 2001a; Swee et al. 2009). Two EDA 
splice variants differing by only two amino acids (Yan et al. 2000) bind to distinct receptors: 
EDA1 binds to EDA receptor (EDAR), and EDA2 binds to X-linked EDAR (XEDAR/EDA2R) 
(Tucker et al. 2000; Yan et al. 2000). EDA1-EDAR interactions mediate development of 
ectodermal appendages, while EDA2-XEDAR may serve as downstream effectors of the p53-
induced anti-proliferative response in colon cancer (Tanikawa et al. 2010). Fully or partially 
inactivating mutations of the gene EDA provoke XLHED and non-syndromic tooth agenesis, 
respectively (Mues et al. 2010). Remarkably, human, dog, cow and mouse EDA are 100% 
identical in their 145 amino acid-long receptor-binding domains, 98% identical to chicken EDA 
and 63% identical (82% similar) to a fish EDA (Gasterosteus acuelatus). During hair placode 
formation in mice, EDA is one of the most apical signaling molecules downstream of Wnt. EDA 
is in turn essential, via NF-κB activation, for sustained Wnt activity (Zhang et al. 2009). Primary 
hair placodes do not form in Eda-deficient mice, teeth are present but small and abnormally 
shaped, sweat glands are missing, and a number of other glands are either absent or reduced 
(Gruneberg 1971).  
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Transgenic expression of EDA1 in the skin of wild-type mice induced supernumerary tooth 
and mammary gland formation, longer hair and nails, and enlarged sebaceous glands (Mustonen 
et al. 2003). In Eda-deficient mice, the transgene stimulated formation of guard hairs, sweat 
glands and induced sebaceous glands hypertrophy (Cui et al. 2003). Repression of transgenic 
EDA1 in adult mice normalized sebaceous glands, indicating a limiting role of EDA1 also in 
some adult structures (Cui et al. 2003). The prenatal or perinatal, but not adult, administration of 
recombinant EDA1 or of agonist anti-EDAR antibodies to Eda-deficient mice or dogs 
ameliorated the EDA-deficient phenotype, paving the way for protein replacement therapy in 
XLHED (Casal et al. 2007; Gaide and Schneider 2003; Kowalczyk et al. 2011). Thus, early 
diagnosis of EDA-deficiency in humans is warranted, particularly since an EDA replacement 
drug has been under investigation for use in newborn infants with XLHED 
(www.clinicaltrials.gov NCT01775462 and NCT01992289). However, early diagnosis of 
XLHED is not trivial.  If family history suggests a risk, and if this is known to the doctor, 
diagnosis can sometimes be established prenatally when ultrasound examination reveals a 
significant deficit of tooth germ formation (Wunsche et al. 2015), or at birth when an array of 
clinical features such as absence of sweat gland openings in the epidermis, skin dryness or 
specific craniofacial abnormalities can be observed. Sometimes, diagnosis is only made in the 
second year of life upon failure of tooth eruption. Definitive evidence of XLHED as opposed to 
other forms of ectodermal dysplasia or tooth agenesis is provided by identification of the 
causative mutation in EDA (Burger et al. 2014; Schneider et al. 2011). 
In this study, we measured EDA in serum, saliva and dried blood spots. We report the 
detection of circulating EDA that is capable of binding to receptors, contains the protein’s 
collagen domain and displays a predominance of the EDA1 over the EDA2 isoform. EDA levels 
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were high in fetuses and newborn, lower in adults, and very low to absent in XLHED patients, in 
line with the known roles of EDA during development, adulthood and disease. These results 
indicate the possibility of diagnosing XLHED by measuring EDA and its receptor-binding ability 
in biological fluids. 
 
MATERIAL AND METHODS 
Animals – K14-Eda-A1 transgenic mice, Edar-deficient OVE1B mice, Eda-deficient Tabby 
mice and their wild-type controls were as described (Kowalczyk et al. 2011; Kowalczyk-Quintas 
et al. 2014b; Mustonen et al. 2003). Mice were handled according to guidelines and under the 
authorization of the Swiss Federal Food Safety and Veterinary Office (authorization 1370.6 to 
PS) or in accordance with the guidelines and with approval from the Finnish National Board of 
Animal Experimentation.  
Human samples – Unstimulated saliva and serum samples were obtained from adult patients 
affected by XLHED, carriers of EDA mutations or non-affected controls (age range: 21 to 52 
years-old for all groups). Sera were also prepared from cord blood of neonates of from cord 
blood of pre-term babies. In some cases, blood was applied directly onto filter paper cards for 
blood sampling (Perkin-Elmer). Samples were obtained with informed consent at the University 
Hospital of Erlangen. All samples were stored at -70°C. Analyses were performed in Lausanne 
under the approval of the Commission cantonale d’éthique de la recherche sur l’être humain, 
Lausanne.   
Antibodies, recombinant proteins and plasmids – Anti-EDA antibodies EctoD2 and 
biotinylated EctoD3, EDAR-Fc, XEDAR-Fc and BMCA-Fc were as previously described 
(Kowalczyk-Quintas et al. 2014b; Schneider et al. 2001a; Schneider et al. 2001b). Fc-EDA1 
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(EDI200) was provided by Edimer Pharmaceuticals. Anti-EDA monoclonal antibody Renzo-2 is 
commercially available (Enzo Life Sciences, ALX-522-038). Sequences of proteins encoded by 
plasmids used for this study are listed in appendix Table 1. 
Affinity purification of EDA –EctoD2 and EctoD3 were coupled at 5 mg/ml to NHS-
activated Sepharose (GE Healthcare), used to capture EDA in 500 ml of fetal calf serum, washed 
extensively with PBS and eluted with 50 mM citrate-NaOH pH 2.7. The eluate was neutralized 
with 1 M Tris-HCl pH9, concentrated and buffer was exchanged for PBS with a 30 kDa cutoff 
centrifugal concentrator device. 
Deglycosylation – Denatured EDA samples were digested with peptide N-glycanase F 
according to manufacturer’s instructions (NewEngland Biolabs).  
Immunoprecipitations and Western blot – EDA was immuno-precipitated for 16 h at 4°C 
with 10 µl of Protein A-Sepharose beads and 1 µg of EDAR-Fc or of XEDAR-Fc in 500 µl of 
PBS. Beads were collected in mini columns (Schneider et al. 2014), washed with PBS, and 
eluted with 15 µl of 100 mM citrate-NaOH pH 3. The eluate was neutralized with 5 µl of 1 M 
Tris-HCl pH9. EDA was also incubated for 16 h at 4°C with 10 µl of heparin-Sepharose beads in 
500 µl of PBS. Beads were washed with PBS and eluted with PBS, 0.8 M NaCl. Western blot 
was performed according to standard protocols with samples heated in denaturing and reducing 
conditions for 5 min at 70°C, because EDA tends to aggregate when boiled. Western blots were 
revealed with Renzo-2 at 1 µg/ml, followed by horseradish peroxidase-coupled anti-mouse 
secondary reagent and ECL. When required, the membrane was probed again with horseradish 
peroxidase-coupled anti-human IgG.  
AlphaLISA – Five µl of samples (e.g. serum diluted 1/2 or undiluted saliva with or without 
pre-depletion on ELISA plates coated with BCMA-Fc, EDAR-Fc or EctoD2) were mixed with 
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biotinylated EctoD3 at 15 ng/ml and 0.5 µg of EctoD2 acceptor beads, and signal was recorded 
with an Enspire plate reader (Perkin-Elmer). Standard curves were generated with Fc-EDA1 
diluted into buffer or into XLHED serum or saliva as indicated. For the measurement of EDA in 
dry blood spots, blood was eluted from filters papers in PBS, then immunoprecipitated with 0.2 
µl of EctoD2 acceptor beads for 1 h at room temperature prior to measurement by AlphaLISA. 
Further details are available in the online supplemental appendix.  
Gel permeation chromatography – 300 µl of serum from human cord blood with high EDA 
content, or from normal human serum with low EDA content, were loaded onto a Superdex 200 
column equilibrated and eluted in PBS. 1 ml fractions were collected. EDA was measured in 
these fractions by AlphaLISA.  
Statistics – Statistics were performed by one-way analysis of variance with Bonferroni’s 
multiple comparison tests using Prism. P values lower than 0.05 were considered significant. 
 
RESULTS  
Specific detection of EDA in serum reveals higher circulating EDA levels in the fetal and 
newborn stages compared to adult – ELISA experiments using a previously characterized pair of 
mouse IgG1 anti-EDA antibodies (EctoD2 and EctoD3) (Kowalczyk-Quintas et al. 2014b) 
indicated the feasibility of detecting endogenous EDA in adult serum (appendix Fig. 1). When 
used in a homogenous AlphaLISA assay (Eglen et al. 2008), this pair of antibodies detected a 
standard of Fc-EDA1 diluted in EDA-deficient serum with a sensitivity of about 0.1 ng/ml in as 
little as 2.5 µl of serum. Signals obtained in a panel of XLHED sera were consistently very low 
(Fig. 1A,B). In this cohort of XLHED patients, the majority is not expected to produce any 
soluble EDA protein as a consequence of frameshift mutation, exon deletion or duplication, 
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splice site mutation or mutations affecting the furin cleavage site (Table 1). In two patients with 
point mutations in the extracellular domain that may preserve the EDA protein, EDA levels were 
higher (0.15 ng/ml) and similar to those found in three carriers, one of which was severely 
affected by XLHED. These levels remained lower than the average EDA level in adult sera (0.7 
ng/ml) or in cord blood sera (2.5 ng/ml) (Fig. 1B). We found no gender differences of EDA 
levels in wild-type humans, neither at birth nor in adults. EDA levels reached 4 ng/ml in cord 
blood sera of two pre-term babies, similar to what was measured in fetal calf serum. EDA was 
present at only 1.5 ng/ml in a third pre-term baby whose pre-term delivery was due to a 
generalized infection. Taken together, these results indicate that circulating EDA levels are 
significantly higher in premature and newborn babies than in adults, and very low or at 
background in EDA-deficient XLHED patients (Fig. 2C). 
 
Low levels of circulating EDA in mice – EDA levels in wild-type adult mouse serum were 
low (0.13 ng/ml), but higher than those in an EDA-deficient serum. Curiously, circulating EDA 
levels in EDAR-deficient or in EDA1-transgenic mice, where the transgene is expressed in the 
skin under a keratin-14 promoter, were not different from wild-type (Fig. 1D). 
 
A fraction of circulating wild-type EDA is capable of binding to EDAR  – Antibodies used 
in this study recognize and inhibit native forms of both EDA1 and EDA2 and therefore cannot 
distinguish between the protein products of the two splice variants (Kowalczyk-Quintas et al. 
2014b). EDAR however specifically binds to EDA1, as does its recombinant protein EDAR-Fc 
(Schneider et al. 2001a; Yan et al. 2000). Using a set of three different pre-depletions, including 
one on EDAR-Fc, it was possible to estimate that about three quarters (52 - 94%) of wild-type 
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EDA in the circulation can bind to EDAR. We have not been able to further characterize the 
fraction of EDA that does not bind to EDAR-Fc: this could be inactive EDA, EDA in complex 
with endogenous soluble receptors or heteromers of EDA1 and EDA2. Pre-depletion with 
EDAR-Fc was also successful in two carriers and in a patient with the point mutation V262F 
(Fig. 2A-C). The later XLHED patient was rather mildly affected, with oligodontia and 
moderately reduced ability to sweat. Binding to EDAR was however defective in a severely 
affected carrier, in a patient with the point mutation M364R and in a few XLHED patients with 
EDA levels slightly above background, suggesting that these circulating EDA molecules are not 
functional (Fig. 2B,C). The patient with the mutation M364R is severely affected, with only 5 
teeth and very little ability to sweat. In conclusion, the quantification of serum EDA protein 
concentration is in itself a valuable biomarker of EDA function, but combined with the 
measurement of EDA receptor-binding activity can further distinguish between hypomorphic and 
fully inactivating mutations. 
 
Detection of EDA in saliva and in dry blood spots – Low levels of EDA, which could be 
depleted on EDAR-Fc, were detected in wild-type but not in XLHED adult saliva (appendix Fig. 
2). Interestingly, signals obtained with recombinant Fc-EDA1 were 4- to 5-fold lower in EDA-
deficient serum compared to saliva or assay buffer (Fig. 2D). Thus, as exemplified for fetal calf 
serum, EDA in serum is underestimated about 5-fold (Appendix Fig. 2B) unless the standard 
curve is also measured in (EDA-deficient) serum (Fig. 1A). Moreover, EDA could be detected in 
dried blood samples. For this purpose, dry blood was eluted from filter paper in PBS, then 
immunoprecipitated with EctoD2-coupled AlphaLISA acceptor beads to circumvent the 
quenching effect of concentrated hemoglobin, and measured for EDA by AlphaLISA. In this 
  Endogenous ectodysplasin A  
 
 10 
procedure, the yield of Fc-EDA immunoprecipitation was about 50%, recovery of dry Fc-EDA 
from filter paper was about a third, and the combined yield of both procedures approached 20%  
(appendix Fig. 2). With this protocol, signals were obtained in wild-type adult blood and wild-
type cord blood eluted and immuno-precipitated from 6-mm diameter filter paper punches, while 
only background signals were found with an adult XLHED blood processed in parallel (Fig. 3C). 
These measures repeated at different time points after blood collection always showed higher 
EDA signals in wild-type adult or cord blood than in the control XLHED blood (R156QfsX2) 
from 3 days to more than a month after blood collection (Fig. 3C). EDA signals detected in cord 
blood were sometimes, but not always, higher than those of adult blood. The qualitative nature of 
these results perhaps reflects a sub-optimally normalized procedure. In conclusion, these results 
demonstrate the feasibility of measuring EDA in dry blood spots and in saliva.  
 
Circulating bovine EDA is N-glycosylated, contains the collagen domain and exists 
predominantly as the EDA1 isoform with a minority of the EDA2 isoform – Circulating 
endogenous EDA was affinity-purified from fetal calf serum on anti-EDA antibodies, then 
immuno-precipitated with recombinant EDAR-Fc or XEDAR-Fc. Flag-tagged forms of EDA1 
and EDA2 used as controls bound to EDAR-Fc and XEDAR-Fc, respectively (Fig. 4A). 
Endogenous EDA from two independent EDA preparations precipitated preferentially with 
EDAR-Fc and to a lesser extent with XEDAR-Fc (Fig 4A). Endogenous EDA migrated with a 
molecular weight of about 35 kDa under denaturing conditions, larger than Flag-EDA1, which 
contains only the TNF homology domain, but at the size of transfected, naturally processed full-
length EDA1, suggesting that both the collagen and TNF homology domains are present in 
circulating EDA. Deglycosylation with peptide N-glycanase F reduced the size of endogenous 
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EDA from 35 to 29 kDa, and that of a minor fragment of 22 kDa to 18 kDa (Fig. 4B). This 
smaller fragment probably corresponds to the TNF homology domain alone. Recombinant EDA 
is not fully N-glycosylated, generating a characteristic doublet in the Western blot (Fig. 4A) 
(Schneider et al. 2001a), while endogenous EDA is almost fully N-glycosylated. The absence of 
intermediate glycosylation products between the 22 and 18 kDa bands in partially digested EDA 
further suggests that endogenous EDA, like transfected EDA expressed in cultured cells, carries 
a single N-linked glycan (Fig. 4B). 
Endogenous EDA and naturally cleaved EDA both bound to heparin-Sepharose, while a 
mutant of the proteoglycan-binding domain hardly did so (Fig. 4C). Flag-tagged EDA1 and 
EDA2 lacking the proteoglycan-binding domain did not bind to heparin-Sepharose either (Fig. 
4C). These data suggest that endogenous EDA has a functional proteoglycan-binding domain. 
Finally, the native size of human EDA in cord blood serum was estimated by size exclusion 
chromatography to be ~200 kDa (Fig. 4D). A calculated size ratio of 5.7 between native and 
denatured EDA suggests that EDA circulates in blood as a hexamer or, if the collagen domain 
confers to the protein a rod-like shape, as a non-globular trimer. In summary, endogenous bovine 
EDA is a soluble glycoprotein containing the proteoglycan-binding, collagen and TNF homology 
domains with a predominance of the EDA1 over the EDA2 isoform. Its posttranslational 
modifications appear to be more homogeneous that those of transfected EDA expressed in 
cultured cell lines.  
 
DISCUSSION 
In this study, high levels of EDA were detected in sera of fetuses and newborns, in good 
agreement with the known timing of EDA function in the development of ectodermal 
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appendages (Mikkola 2008). Lower levels of EDA were also found in adult sera and only 
background levels in XLHED sera. The size of endogenous EDA under native and denaturing 
conditions, its glycosylation and receptor binding patterns correspond to what we know about the 
protein (Kowalczyk-Quintas and Schneider 2014).  
Expression of EDA mRNA has been reported in various adult human tissues (Montonen et 
al. 1998) and in adult mice EDA and EDAR have been implicated in regulation of the hair cycle 
(Fessing et al. 2006). In addition, hair-associated sebaceous glands responded to EDAR 
stimulation, suggesting that sebaceous glands are likely targets of EDA in the adult (Kowalczyk-
Quintas et al. 2014a). Other tissue candidates for the action of EDA in adults are salivary glands 
(Hill et al. 2014) and wounded skin (Garcin et al. 2016) that both respond to EDAR agonists. It 
therefore makes sense to find EDA expressed in adults.  
The measurement of EDA combined with pre-depletion on recombinant receptors showed 
that the main circulating isoform is EDA1, but that lower levels of EDA2 are also present in fetal 
calf serum. In principle, depletion of sera with recombinant XEDAR should give direct 
information on the proportion of circulating EDA2, but in practice the reduction observed was 
too low for reliable interpretation. The co-existence of EDA1 and EDA2 in serum is interesting 
in terms of possible heteromer formation. In the TNF family, heteromers of lymphotoxin-
α/lymphotoxin-β as well as heteromers of BAFF/APRIL, whose receptor binding specificities 
can be distinct from those of homotrimers, have been structurally characterized (Schuepbach-
Mallepell et al. 2015; Sudhamsu et al. 2013). It will be interesting in the future to investigate 
whether EDA1/EDA2 heteromers can be produced, and, if so, what receptor(s) they bind.   
In the adult, EDA expression has been described in skin epithelium, hair follicles and teeth, 
but also in organs where EDA has no known functions such as the central nervous system, 
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kidney or prostate (Montonen et al. 1998). The origin of circulating EDA reported here in three 
different species remains to be determined. It may not originate exclusively from the skin 
because mice overexpressing EDA1 in the epidermis, where it induces pronounced 
morphological alterations in various appendages (Mustonen et al. 2003), had normal levels of 
circulating EDA. The same was true for complete deletion of the Edar gene in Ove1B mice 
(Headon and Overbeek 1999), indicating that endogenous EDAR does not deplete or regulate 
EDA levels in the circulation. EDA contains a basic domain that promotes its binding to heparin 
and proteoglycans (Swee et al. 2009), and it is conceivable that EDA produced in the skin, even 
in EDA1 transgenic mice, exerts its effects locally without systemic implication.  
Regarding diagnosis of EDA-deficiency, the detection of EDA in serum, or in dried blood 
spots, offers an alternative to phenotypic or genetic screening of newborns. In routine dental 
practice, blood samples are not taken, but saliva is readily accessible. The measurement of EDA 
in saliva could provide useful information with regard to the cause of missing teeth. Selective 
tooth agenesis can be caused, among other reasons, by mutations in genes encoding master 
regulators of tooth formation such as PAX9 and MSX1, elements of the WNT signaling pathway 
such as WNT10A or AXIN2, the WNT target BMP4, or EDA, EDAR or EDARADD (Bergendal 
et al. 2011; Huang et al. 2013; Stockton et al. 2000; van den Boogaard et al. 2012). In cases of 
non-syndromic tooth agenesis, the EDA protein must be produced in vivo at least to some extent, 
however its capacity to bind to EDAR is often decreased (Mues et al. 2010). The measurement of 
EDA with or without pre-depletion on recombinant EDAR provides information on both 
expression levels and functionality of EDA. 
In conclusion, this study provides the first description of soluble EDA in blood and saliva, 
characterizes several of its properties including receptor binding, and documents its expression 
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levels throughout life and disease. Although the origin and function of circulating EDA remains 
to be determined, its concentration and receptor-binding capacity correlate well with its function 
in vivo and could therefore be used as specific biomarkers to facilitate the diagnosis of XLHED 
or unexplained tooth agenesis.   
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1. Human EDA levels are higher in cord blood than in the adult circulation. 
A. EDA was measured in human sera, using Fc-EDA1 diluted in EDA-deficient human serum as 
a standard. EDA was also measured in fetal calf sera, and in sera of adult mice of the indicated 
genotypes. The pre-term baby at 29 weeks suffered from a generalized infection (infect). The 
child was 7 years old. Mean of duplicates ± SEM. Black circles: males. White circles: females. 
B. Blow up of the graph with XLHED and related sera. Letters refer to sample ID of Table 1. 
C. Comparison of the mean ± SEM of XLHED (HED; n=12), wild-type adult (WT; n=27), cord 
blood (n=12), pre-term (n=3) and fetal calf (n=3) sera. A one-way ANOVA with Bonferroni’s 
multiple comparison tests was performed. *: p<0.05, ** p<0.01, *** p<0.001. 
D. Blow-up of the graph with mouse sera. def: deficient. Tg: transgenic. 
This experiment was performed twice with comparable results. 
 
Figure 2. Wild-type, but not mutated EDA in serum can bind to EDAR.  
A. EDA levels in normal adult sera after pre-depletion on a control protein (BCMA-Fc), or on 
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EDAR-Fc, or on EctoD2. Percentages of depletion with EDAR-Fc are indicated at the bottom. 
Mean of duplicates ± SEM. 
B. Same as panel A, but for adult XLHED and related sera. Letters refer to sample ID of Table 1. 
Mean of duplicates ± SEM. Percentage depletion was not calculated for patient “b”, because the 
lack of depletion on EctoD2 questioned the origin of this signal. 
C. Scatter plot representation of the percentage of EDA depletion on EDAR-Fc for the indicated 
groups of persons. 
D. AlphaLISA was used to measure Fc-EDA1 at different concentrations is assay buffer (black 
circles), or in saliva of an XLHED patient (opened triangles), or in serum of an XLHED patient 
(black inverted triangles). The lower limit of quantification (LLQ) is shown by a dotted line. 
Experiments of panels A to D were performed once in the format presented. Similar results were 
obtained with the analysis of isolated saliva samples. Mean of duplicates ± SEM. 
 
Figure 3. Detection of endogenous EDA in blood dried onto filter paper. 
Blood from a normal adult (A), blood from an adult XLHED patient (X) and normal cord blood 
(C) were dried onto filter paper. 3, 10, 17, 31 and 45 days later, blood was eluted from 6 mm 
diameter punches of blood-impregnated filter paper, immuno-precipitated with EctoD2-coupled 
AlphaLISA acceptor beads and tested for the presence of EDA. 
This experiment was performed once in this format. Mean of duplicates ± SEM.  
 
Figure 4. Biochemical characterization of endogenous EDA in human and bovine sera. 
A. EDA from fetal calf serum was affinity-purified on immobilized EctoD2 and EctoD3, while 
recombinant EDA (naturally cleaved or Flag-tagged) expressed in 293T cells were collected in 
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conditioned supernatant. EDA proteins were immuno-precipitated with EDAR-Fc (E) or 
XEDAR-Fc (X) and analyzed by Western blot with anti-EDA Renzo2 (top panels). EDAR-Fc 
and XEDAR-Fc were detected by re-probing the membrane with anti-Fc. Amino acid residues of 
EDA are indicated in brackets. PG mut: mutated proteoglycan-binding domain. GKKA, GEEA: 
relevant wild-type and mutated sequences in the proteoglycan-binding domain of EDA.  
B. EDA proteins were (partially) digested with or without peptide N-glycanase F (PNGaseF) and 
analyzed by anti-EDA Western blot. 
C. The indicated EDA protein were captured on heparin-coupled beads, eluted with salt, and 
analyzed by Western blot anti-EDA. Mut: mutated proteoglycan-binding site. 
D. Gel filtration elution profiles of human sera with high (cord serum) or low (adult serum) EDA 
content. EDA was detected in fractions by AlphaLISA (single measures). Elution positions of 
molecular weight standards (in kDa) are indicated. EDA concentration in fraction of the elution 
of control serum was probably below the detection limit. 
Experiments of panels A to D were all performed three times with similar results. 
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Ectodysplasin A in biological fluids and diagnosis of ectodermal dysplasia.      
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Mikkola, Holm Schneider and Pascal Schneider 
 
 
Appendix Figure 1. Detection of EDA in human serum by ELISA. 
A. Dose-dependent detection of recombinant Fc-EDA1 in assay buffer by sandwich ELISA with 
a pair of anti-EDA monoclonal antibodies: EctoD2 at capture, and biotinylated-EctoD3 to reveal.  
B. Signal obtained with the EDA sandwich ELISA on 11 normal adult human sera (opened 
symbols) or one serum of an adult XLHED patient with a premature stop codon in EDA 
(c.64_71dupAGCCAGGG, p.C25AfsX35) (black symbols). Prior to performing the ELISA, sera 
were depleted twice on an irrelevant receptor (BCMA-Fc), or on EDAR-Fc, or on the capture 
antibody EctoD2. Result of a one way ANOVA considering WT sera only, with Bonferroni’s 
multiple comparison test, are shown: *: p<0.05, ** p<0.01, *** p<0.001. The experiment was 
performed once in this format (and twice on isolated samples to set up conditions). 
 
A promising sandwich ELISA for the 
detection of endogenous EDA in serum – A 
previously characterized pair of mouse IgG1 
anti-EDA antibodies (EctoD2 and EctoD3) 
(Kowalczyk-Quintas et al. 2014) detected 
recombinant Fc-EDA1 with a sensitivity of 
about 0.3 ng/ml in a sandwich ELISA 
(appendix Fig. 1A); it was therefore tested for 
its potential ability to detect endogenous levels 
of circulating EDA in adult human sera. 
Human sera produced signals that were 
significantly diminished by pre-incubation on 
EDAR-Fc, a recombinant form of the EDA1 
receptor, and even more decreased by pre-
incubation with the capture antibody EctoD2 
(Fig. 1B). Unexpectedly, a signal was also 
obtained with the serum of a patient null for 
the portion of the EDA protein recognized by 
both capture and revelation antibodies 
(mutation c.64_71dup AGCCAGGG, 
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p.C25AfsX35) (Fig. 1B). However, this signal 
was characterized as unspecific because it was 
insensitive to depletion with EDAR-Fc or with 
the capture antibody (appendix Fig.1B). Taken 
together, these results suggest that the 
sandwich ELISA with EctoD2 and EctoD3 
anti-EDA antibodies is sensitive enough to 
detect endogenous levels of circulating EDA, 
that at least a fraction of this EDA is the EDA1 
splice variant capable of binding to EDAR, but 
that a background signal independent of 
EctoD2 binding can sometimes be present and 
confound interpretation of results. A relatively 
reagent- and time-consuming strategy 
involving pre-depletions on the capture 
antibody, on EDAR-Fc and on an irrelevant 
receptor-Fc (BCMA-Fc) allows distinction 
between specific and unspecific signals. 
Therefore, although EDA is well-known for its 
involvement in embryogenesis, a circulating 
form can be detected in adult human sera.  
 
Principle of AlphaLISA – In an AlphaLISA 
assay, excitation of a phthalocyanine 
photosensitizer at 680 nm produces short-lived 
(4 µs) oxygen singlet, which, when reaching 
an acceptor bead present within its 200 nm 
diffusion diameter, converts a thioxene group 
into a di-keto derivative with concomitant light 
emission at 340 nm. This light is quenched by 
a nearby Europium chelate that emits the final 
signal at 615 nm (Eglen et al. 2008). This 
system is particularly suited for measures in 
sera, even hemolysed, because absorption 
spectra of hemoglobin and other serum 
proteins are low above 600 nm. 
 
 
Appendix Figure 2. Low levels of EDA can be detected in saliva. 
A. EDA levels were measured by AlphaLISA in freshly collected saliva from twenty healthy 
adults, after pre-depletion of the saliva on BCMA-Fc, EDAR-Fc or on the anti-EDA antibody 
EctoD2. EDA was quantified relative to a standard curve of Fc-EDA1 diluted in assay buffer.  
B. BCMA-Fc, EDAR-Fc and EctoD2 coated in an ELISA plate were used to deplete saliva from 
three adults, and the exact same receptors were used immediately afterwards to deplete EDA in 
fetal calf serum (FCS). EDA was subsequently monitored by AlphaLISA in these samples. Sera 
from an XHLED patient (X) and from cord blood (C) were measured in parallel. Note that data 
for the saliva of volunteers 1, 2 and 3 are identical to those shown in panel A, except for the Y-
axis of the graph. 
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C. EDA levels were monitored by AlphaLISA in frozen saliva samples from 21 healthy wild 
type volunteers (number 1 to 20 are identical to those of panel A, except for the freeze and thaw 
cycle). EDA was quantified relative to a standard curve of Fc-EDA1 diluted in saliva of an 
XLHED patient. The lower limit of quantification is indicated by a dotted line. 
Experiments of panels A, B and C were performed once in the format presented. Similar results 
were obtained with the analysis of isolated saliva samples. Mean of duplicates ± SEM. 
 
Low levels of EDA are present in saliva 
– An average of 15 pg/ml of EDA was 
detected in freshly collected saliva of twenty 
healthy volunteers. About 80% of this EDA 
could be depleted on EDAR-Fc (appendix Fig. 
2A). The depletion reagents were not 
destroyed by saliva because they remained 
active to subsequently deplete EDA in a 
sample of fetal calf serum with high EDA 
levels (appendix Fig. 2B). Comparable EDA 
levels were found after saliva had been frozen 
(at -70°C), in all cases at levels higher than 
background measured in a saliva sample from 
an XLHED patient (appendix Fig. 2C). 
Interestingly, signals obtained with 
recombinant EDA in saliva of an XLHED 
patient versus assay buffer were only slightly 
reduced, indicating no major quenching effect 
of saliva in this assay. This contrasts with the 
measurement of recombinant EDA spiked into 
the serum of an XLHED patient, for which 
signals obtained were lowered 4- to 5-fold 
(appendix Fig. 2D). When EDA is measured in 
serum, it therefore appears important that the 
standard curve is also measured in (EDA-
deficient) serum to avoid a 5-fold 
underestimation of serum concentrations, as 
seen for fetal calf serum in Appendix Fig. 2B 
versus Fig. 1A. In summary, low levels of 
active EDA are present in normal human 
saliva. 
 
 
Appendix Figure 3. Setup experiments for the measure of EDA in dry blood spots. 
A. 0.1 µl of EctoD2-coupled AlphaLISA acceptor beads were used to monitor Fc-EDA1 at the 
indicated concentrations in 5 µl of assay buffer (closed circles, “direct”). In parallel, 0.1 µl of 
acceptor beads were used to immuno-precipitate a five times larger volume (25 µl) of Fc-EDA1. 
Beads were washed and measured as performed for the direct assay (opened circles, “IP”). The 
calculated yields of immuno-precipitation at different concentrations of Fc-EDA1 are indicated 
in the graph.   
B. EDA was measured directly in 2.5 µl of serum of an XLHED patient (X) or in cord serum 
(C). EDA was also measured in 4 µl of the same serum that had been dried onto filter paper, then 
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eluted in PBS, or in 4 µl of adult blood (B) that had been spiked with the indicated concentration 
of Fc-EDA1, then dried onto filter paper and eluted in PBS. Finally, EDA was measured in 20 µl 
of these same samples dried onto filter paper, eluted in PBS and immuno-precipitated with 
EctoD2-coupled AlphaLISA acceptor beads. 
 
Detection of EDA in blood spots dried onto 
filter paper – The acceptor beads of the 
AlphaLISA are covalently coupled to an anti-
EDA antibody and can be used to immuno-
precipitate EDA with a yield of about 50% at 
non-saturating concentrations (appendix Fig. 
3A). In addition, about a third of the content of 
EDA in cord blood serum could still be 
detected when cord blood serum was first 
dried overnight at room temperature on a filter 
paper and then eluted from the filter (Fig 5B). 
Upon combination of both procedures, i.e. 
when cord blood serum dried onto filter paper 
was eluted and then immuno-precipitated with 
acceptor bead, the yield of measurable EDA 
recovery was about 20% (appendix Fig. 3B). 
We then evaluated whether a similar procedure 
could be applied to full blood samples. When 
normal adult blood was dried onto filter paper, 
eluted and measured for EDA, values lower 
than those measured in XLHED serum were 
obtained, indicating a quenching effect of 
blood (appendix Fig. 3B). Indeed, eluted blood 
samples are rich in hemoglobin and very dark 
in color. Despite this, a positive signal could 
be obtained when blood was spiked with 200 
ng/ml of EDA prior to spotting onto filter 
paper (appendix Fig. 3B). Most if not all of 
this quenching problem was overcome by 
EDA immuno-precipitation from eluted blood: 
EDA signals in normal blood were higher than 
those in XLHED serum and increased in a 
dose-dependent manner in blood spiked with 
increasing amounts of Fc-EDA1 (appendix 
Fig. 3B). 
 
Supplemental methods 
Sandwich ELISA – ELISA plates were 
coated with EctoD2 at 1 µg/ml in PBS, then 
blocked and incubated for 1 h at room 
temperature with 100 µl of serum that had 
been pre-depleted on BCMA-Fc, EDAR-Fc or 
EctoD2. After washing, EDA was revealed for 
1 h at 37°C with 1 µg/ml of biotinylated 
EctoD3, followed by horseradish peroxydase-
coupled streptavidin and revelation with ortho-
phenylenediamine as described (Schneider et 
al. 2014). For the pre-depletions, ELISA plates 
were coated with BCMA-Fc, EDAR-Fc or 
EctoD3 at 1 µg/ml in PBS, in duplicates, then 
blocked and washed. 100 µl serum was applied 
in the first well for 6 h at room temperature, 
then passed to the second one overnight at 
4°C, prior to transfer to the main assay plate. 
 
AlphaLISA – Monoclonal antibody 
EctoD2 (50 µg) was coupled for 24 h at 37°C 
to 500 µg of AlphaLISA acceptor beads 
(Perkin-Elmer) in 200 µl of 27 mM Na-
phosphate pH8, 5 mM NaBH3CN and 0.03% 
Tween-20. Reaction was terminated by 
addition of 50 µl of carboxymethoxylamine at 
65 mg/ml in 0.8 M NaOH for 1 h at 37°C. 
Beads were washed twice in 0.1 M Tris-HCl 
pH8, then stored at 4°C and at a concentration 
of 5 mg/ml in PBS 0.05% Proclin-300. Assays 
were performed in white 384-well plates by 
mixing 5 µl of samples, usually serum diluted 
1/2 in assay buffer (Perkin-Elmer), or 
undiluted saliva, with 20 µl of biotinylated 
EctoD3 at 15 ng/ml and 0.5 µg of EctoD2 
acceptor beads in assay buffer. After 1 h 
incubation at room temperature, 1 µg of 
streptavidin-coupled donor beads in 25 µl of 
assay buffer was added. Emission at 615 nm 
after excitation at 680 nm was recorded with 
an Enspire plate reader (Perkin-Elmer). 
Standard curves were performed with 5 µl of 
recombinant Fc-EDA1 diluted into buffer, or 
into XLHED serum diluted 1/2, or into 
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XLHED saliva as indicated in the figure 
legends. In some cases, sera or saliva samples 
were pre-depleted on ELISA plates coated 
with BCMA-Fc, EDAR-Fc or EctoD2 as 
described under “Sandwich ELISA”.  
In some instances, recombinant Fc-EDA1, 
or serum, or blood, or blood spiked with Fc-
EDA1 were spotted onto filter paper cards for 
blood sampling. After drying and storage at 
4°C until use, 6 mm diameter circles were 
punched in the filter, placed into microtubes 
with a hole at the bottom, themselves placed 
into intact microtubes. Filters were eluted with 
40 µl of PBS by centrifugation. Eluates were 
either measured directly by AlphaLISA, or 
immunoprecipitated with 0.2 µl of EctoD2-
coupled acceptor beads for 1 h at room 
temperature. Beads were then pelleted by 
centrifugation at 8000 rpm (6200 x g) in a 
tabletop centrifuge, washed with assay buffer, 
and measured by AlphaLISA.  
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Appendix Table 1. Plasmids used in this study. 
 
Plasmid Designation Protein encoded Vector 
ps508 Flag-mEDA2 HA signal-Flag-GPGQVQLQVD-mEDA1 (aa 245-389) PCR3 
ps548 Flag-mEDA1 HA signal-Flag-GPGQVQLQVD-mEDA1 (aa 245-391) PCR3 
ps739 hBCMA-Fc Ig signal-EVKLVPRGS-hBCMA (aa 2-54)-VD-hIgG1 (aa 245-470) PCR3 
ps930 hEDAR-Fc hEDAR (1-183)-VD-hIgG1 (aa 245-470) PCR3 
ps1060 hXEDAR-Fc HA signal-DVT-hXEDAR (aa 1-133)-VD-hIgG1 (aa 245-470) PCR3 
ps1752 hEDA1 full hEDA1 (aa 1-391) PCR3 
ps1938 Fc-EDA1 HA signal-hIgG1 (aa 245-470)-hEDA1 (aa 238-391) PCR3 
ps2867 hEDA1 full 
HBD mut 
hEDA1 (aa 1-391) KK177/178EE 
PCR3 
       Flag = DYKDDDDK    HA signal=MAIIYLILLFTAVRG    
       Ig signal=MNFGFSLIFLVLVLKG  HBD mut : heparin binding domain mutant 
 
 
 
